Avalo Therapeutics (AVTX) Cash & Equivalents (2016 - 2025)
Historic Cash & Equivalents for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to $27.0 million.
- Avalo Therapeutics' Cash & Equivalents fell 6706.13% to $27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.0 million, marking a year-over-year decrease of 6706.13%. This contributed to the annual value of $134.5 million for FY2024, which is 171451.11% up from last year.
- Latest data reveals that Avalo Therapeutics reported Cash & Equivalents of $27.0 million as of Q3 2025, which was down 6706.13% from $42.3 million recorded in Q2 2025.
- Avalo Therapeutics' 5-year Cash & Equivalents high stood at $134.5 million for Q4 2024, and its period low was $6.3 million during Q2 2023.
- In the last 5 years, Avalo Therapeutics' Cash & Equivalents had a median value of $38.5 million in 2022 and averaged $49.4 million.
- In the last 5 years, Avalo Therapeutics' Cash & Equivalents crashed by 7630.55% in 2022 and then surged by 171451.11% in 2024.
- Over the past 5 years, Avalo Therapeutics' Cash & Equivalents (Quarter) stood at $54.6 million in 2021, then tumbled by 75.87% to $13.2 million in 2022, then tumbled by 43.71% to $7.4 million in 2023, then skyrocketed by 1714.51% to $134.5 million in 2024, then tumbled by 79.96% to $27.0 million in 2025.
- Its Cash & Equivalents was $27.0 million in Q3 2025, compared to $42.3 million in Q2 2025 and $125.0 million in Q1 2025.